# SentiAR

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sentiar

- Industry: Medical Devices & Equipment
- Headquarters: St. Louis, US
- Website: www.sentiar.com
- Total disclosed funding: $15M
- Latest round: Series B (Apr 11, 2023)
- Investors on record: 10

## About

SentiAR, Inc. is a US-based medical technology company specializing in augmented reality solutions for enhanced visualization of complex anatomical data, focusing on improving procedural outcomes for healthcare professionals.Founded in 2017 in St. Louis, US, SentiAR, Inc. develops augmented reality systems for medical use, specifically the CommandEP system. The founders include Jennifer Silva, Jonathan Silva, and Michael Southworth. The company has raised a total of USD 8.5 mn, with its most recent funding round being a Series B completed on April 11, 2023, led by Harmonix and MedVenture Partners with additional participation from other investors. The company's current valuation stands at USD 24.156 mn.SentiAR's core product, the CommandEP system, leverages augmented reality to provide interactive 3D visualizations of the human heart, utilizing real-time data from catheters and 3D electroanatomic mapping systems. This product serves a diverse range of medical professionals, including radiologists, cardiologists, neurologists, and anesthetists, facilitating minimally invasive interventional procedures that result in smaller entry wounds and quicker recovery times for patients. By presenting complex anatomical data in an intuitive format, the CommandEP system enhances procedural accuracy and aids physicians in explaining procedures to patients using 3D models. The primary customer base includes hospitals and healthcare institutions globally, particularly in North America and Europe, where the demand for advanced visualization technology in the medical field is increasingly prevalent.SentiAR's revenue model is structured around the sale and implementation of its flagship product, the CommandEP system, which is offered through direct sales to healthcare institutions and hospitals. Transactions typically involve the installation of the system along with ongoing support and training services for medical staff, establishing a B2B engagement. Pricing plans may encompass one-time fees for hardware and software, along with recurring revenue from service agreements or software updates. The company engages directly with its clients to ensure integration and support, fostering long-term partnerships that enhance the value provided to healthcare professionals.In April 2023, SentiAR, Inc. raised USD 8.5 mn in Series B funding led by new investor Cultivate(MD), with participation from Harmonix, MedVenture Partners, and other returning investors. The company plans to utilize this funding for business expansion and to strengthen its partnerships. SentiAR is also focused on developing upcoming products to enhance their offerings, alongside plans for expansion into new geographic markets to increase their presence in the medical technology sector.

## Funding rounds

- Series B, Apr 11, 2023, $8.5M — MedVenture Partners, VCapital, Techwald Holding, Harmonix, QRM Capital
- Series A, Apr 13, 2021, $5.1M — Keiretsu Forum, BioGenerator, Cultivation Capital, VCapital, Techwald Holding, Harmonix, QRM Capital
- Series A, Mar 31, 2020 — Harmonix
- Seed, Sep 6, 2017, $1.1M — BioGenerator, Cultivation Capital, Pinpoint Holdings, LLC, Oakland Capital Partners

## Investors

- BioGenerator (https://capitalatlas.ai/funds/biogenerator) — Seed, Series A
- Cultivation Capital (https://capitalatlas.ai/funds/cultivation-capital) — Seed, Series A
- Pinpoint Holdings, LLC — Seed
- Oakland Capital Partners — Seed
- Harmonix — Series A, Series B
- Keiretsu Forum — Series A
- VCapital (https://capitalatlas.ai/funds/vcapital) — Series A, Series B
- Techwald Holding (https://capitalatlas.ai/funds/techwald-holding) — Series A, Series B
- QRM Capital — Series A, Series B
- MedVenture Partners (https://capitalatlas.ai/funds/medventure-partners) — Series B